Camp4 Therapeutics Corp
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $3.5M | $652,000 | $350,000 | — |
| Research and development | $38.2M | $38.8M | $40.6M | — |
| Operating expenses | $56.1M | $53.7M | $52.2M | — |
| Operating income | -$52.6M | -$53.1M | -$51.9M | — |
| Income tax expense | $0 | $0 | $0 | — |
| Net income | -$80.4M | -$51.8M | -$49.3M | — |
| Balance Sheet | ||||
| Cash and equivalents | $109.5M | $64.0M | $38.4M | — |
| Current assets | $114.1M | $66.4M | $40.0M | — |
| Total assets | $117.8M | $78.3M | $54.9M | — |
| Current liabilities | $15.5M | $9.6M | $7.8M | — |
| Total liabilities | $70.1M | $15.2M | $16.5M | — |
| Stockholders' equity | $47.7M | $63.1M | -$123.7M | -$77.5M |
| Cash Flow Statement | ||||
| Cash from operations | -$29.6M | -$45.6M | -$44.2M | — |
| Depreciation and amortization | $1.6M | $1.7M | $1.7M | — |
| Stock-based compensation | $4.0M | $4.0M | $2.9M | — |
| Capital expenditure | $279,000 | $441,000 | $678,000 | — |
| Free cash flow | -$29.8M | -$46.0M | -$44.8M | — |
| Impairments | $500,000 | $0 | — | — |
Shares outstanding 51.9M · Free float 60.4%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.